Nyxoid
·
- Prescription status not stated
- Everything that fits nowhere else, such as contrast media
- Active substance
- Naloxone
- Made by
- Mundipharma Corporation (Ireland) Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Nyxoid is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings. Nyxoid is indicated in adults and adolescents aged 14 years and over. Nyxoid is not a substitute for emergency medical care.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
BulgariaNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Mundipharma Corporation (Ireland) Limited |
|---|---|
| Active substance | Naloxone |
| Used in | Everything that fits nowhere else, such as contrast media |
| Classification | V03AB15 · Everything that fits nowhere else, such as contrast media |
| Authorised on | 2017-11-09 |
| Last updated by the regulator | 2025-06-12 |
| EMA product number | EMEA/H/C/004325 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).